Healthcare >> Analyst Interviews >> April 4, 2011
Michael Yee brings more than nine years of experience to RBC Capital Markets' biotechnology research team in San Francisco. Most recently, he was named "Best Up and Comer" in the biotechnology sector in Institutional Investor's 2010 All-America Research Team. Mr. Yee joined RBC Capital Markets in 2005, after working at WR Hambrecht & Co, where he covered biotechnology. Mr. Yee also worked at Deutsche Bank Securities Inc. and Thomas Weisel Partners LLC, where he worked in life science tools equity research from 2001 to 2004 . Mr. Yee earned a B.A. in molecular cell biology from the University of California, Berkeley, and an MBA from the University of California, Berkeley, Haas School of Business. Profile
TWST: When we spoke last year we talked about the themes in biotechnology. Three of the themes you identified were M&A activity, a wave of new blockbuster drugs and the impact of health care
